Universitäres Centrum für Tumorerkrankungen Mainz (UCT Mainz)
Klinisch orientierter Schwerpunkt / Johannes Gutenberg-Universität Mainz
Neumann, Helmut; Hassan, Cesare
Diagnosis of early esophageal cancer using blue laser imaging (BLI)DIGESTIVE AND LIVER DISEASE. Bd. 50. H. 10. 2018 S. 977-978
Jansen, L.; Buttmann-Schweiger, N.; Listl, S. et al.
Differences in incidence and survival of oral cavity and pharyngeal cancers between Germany and the United States depend on the HPV-association of the cancer siteORAL ONCOLOGY. Bd. 76. 2018 S. 8-15
Stojanovic, Nikolina; Dekanic, Ana; Paradzik, Mladen et al.
Differential Effects of Integrin alpha v Knockdown and Cilengitide on Sensitization of Triple-Negative Breast Cancer and Melanoma Cells to Microtubule PoisonsMOLECULAR PHARMACOLOGY. Bd. 94. H. 6. 2018 S. 1334-1351
Gaidzik, V. I.; Weber, D.; Paschka, P. et al.
DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemiaLEUKEMIA. Bd. 32. H. 1. 2018 S. 30-37
Labenz, C.; Woerns, M. -A.
Editorial: covert hepatic encephalopathy-silent but seriousALIMENTARY PHARMACOLOGY & THERAPEUTICS. Bd. 48. H. 4. 2018 S. 480-481
Kremer, Andreas; Bowlus, Christopher L.; Neff, Guy W. et al.
Effect of Seladelpar on Pruritus in Primary Biliary Cholangitis: 26-Week Analysis of an Ongoing International, Randomized, Dose Ranging Phase 2 StudyHEPATOLOGY. Bd. 68. H. 6. 2018 S. 1464A-1465A
Stratmann, Jan A.; Michels, Sebastian; Hornetz, Sofia et al.
Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancerJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. Bd. 144. H. 12. 2018 S. 2457-2463
Persico, M.; Flisiak, R.; Abunimeh, M. et al.
Efficacy and safety of glecaprevir/pibrentasvir in renally-impaired patients with chronic hepatitis C virus genotype 1-6 infectionJOURNAL OF HEPATOLOGY. Bd. 68. 2018 S. S292-S292
Bowlus, Christopher L.; Neff, Guy W.; Aspinall, Richard et al.
Efficacy and Safety of Seladelpar, a Selective Peroxisome Proliferator-Activated Receptor Delta Agonist, in Primary Biliary Cholangitis: 52-Week Analysis of an Ongoing International, Randomized, Dose Ranging Phase 2 StudyHEPATOLOGY. Bd. 68. H. 6. 2018 S. 1446A-1447A
Gebauer, J.; Spix, C.; Brabant, G. et al.
Endocrine late effects following childhood cancer treatmentONKOLOGE. Bd. 24. H. 10. 2018 S. 790-796